Regenerative Medicines - Stem Cell Therapy -

About Us

Our team of world-class scientists and biotechnology leadership is devoted to discovering breakthrough medicines that change the standard of medical care for patients.

Sir Martin Evans, Nobel Laureate, and Ajan Reginald, former Global Head of Emerging Technologies at Roche, originally founded the company under the name Cell Therapy Ltd (CTL) in 2009. CTL was rebranded as Celixir in 2016.

Press Releases

Celixir announces US FDA approval of the IND application for cell therapy HeartcellTM

Stratford-upon-Avon, 8 June 2018

Hockey For Heroes Renews Sponsorship with Celixir

Stratford upon Avon, 12 March 2018

Presentations

11th World Congress of Regenerative Medicine & Stem Cell

Singapore | 16 November 2017

European Society of Gene and Cell Therapy Conference

Florence | 18 to 21 October 2016

Presentation by Celixir :

Fixing the So-called Unfixable: Regenerating Untreatable Fixed Myocardial Scar in Heart Failure Patients; A. Reginald, S. Sultan, L. Chapman, M. Evans, K, P. Antonitsis, S. Westaby and K. Anastasiadis

Celixir Posters :

Immunomodulatory Progenitor Cells: A Novel And Safe Allogeneic Therapy For Patients With Ischaemic Cardiomyopathy Undergoing Coronary Artery Bypass Grafting; S. Sultan, A. Reginald, L. Chapman, M. Evans, K, P. Antonitsis, S. Westaby and K. Anastasiadis
Tendoncel Phase II Placebo Controlled Randomized Clinical Trial Results For A Novel Allogeneic Regenerative Topical Medicine In Treatment Of Chronic Tendon Injury; A. Reginald, S. Sultan, A. Mousiadou, L. Chapman, M. Evans & G. Panagiotis

Events

Our Work in Pipeline

Heartcel (IMMUNOMODULATORY PROGENITOR [iMP] CELLS)

PHASE 2 : Our first investigational cardiac regenerative medicine consists...

Tendoncel (PLATELET LYSATE-BASED THERAPY)

PHASE 3 : Our investigational topical gel containing platelet lysate is...

Myocardion (PROGENITOR CELLS OF MESODERMAL LINEAGE [PML])

CLINICAL TRIAL READY : PML cells are being investigated as...